TRIB3 (rs2295490) AG/GG genotypes were found to reduce primary vascular events in patients who received intensive glucose treatment as compared to those receiving standard glucose treatment in type 2 diabetic patients (He et al., 2018). This evidence concerns the gene TRIB3 and type 2 diabetes mellitus.